Blockchain Registration Transaction Record

Quantum BioPharma Partners with Thermo Fisher for Phase 2 MS Trial

Quantum BioPharma signs Study Start-Up Agreement with Thermo Fisher for Phase 2 trial of Lucid-MS, a novel MS therapy targeting demyelination.

This news matters because it highlights a promising new approach to treating multiple sclerosis that goes beyond immune suppression to protect nerve fibers directly. If successful, Lucid-MS could offer a much-needed alternative for patients who don't respond to current therapies. The involvement of Thermo Fisher, a leader in clinical research, adds credibility and resources to the trial, increasing the chances of generating robust data. For investors, this partnership de-risks the development path and could accelerate Quantum BioPharma's timeline, potentially leading to a major breakthrough in MS treatment.